Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.

Current treatment options in oncology - 1 Aug 2017

Maxwell Russell, Jackson Christopher M, Lim Michael

Abstract excerpt

OPINION STATEMENT: Immune checkpoint inhibitors have changed the landscape of cancer immunotherapy and are being integrated into the standard of care for a variety of solid and hematologic malignancies. Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and carries a grave prognosis despite advances in surgical resection, chemotherapy, and radiation therapy. Implementing immunotherapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to B7-H1 Antigen
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to CTLA-4 Antigen

Share to Immunomodulation

Share to Oncolytic Virotherapy

Share to Programmed Cell Death 1 Receptor

Source

Identifiers

PMID: 28785997
DOI: 10.1007/s11864-017-0492-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.PMID 28785997Read ↗

Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trialsSemantic proximity Read ↗

Immune Cell Interplay in the Fight Against GBMSemantic proximity Read ↗

Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future DirectionsSemantic proximity Read ↗

Immunotherapy of Primary Brain Tumors: Facts and Hopes.Semantic proximity Read ↗

Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic playersSemantic proximity Read ↗

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.Semantic proximity Read ↗

Glioma targeted therapy: insight into future of molecular approaches.Semantic proximity Read ↗

Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.Semantic proximity Read ↗

Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases.Semantic proximity Read ↗

Personalized Medicine for GliomasSemantic proximity Read ↗

Integrin blocking peptide reverses immunosuppression in experimental gliomas and improves anti-PD-1 therapy outcomeSemantic proximity Read ↗

Immune Microenvironment in Glioblastoma Subtypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.